From owner-doc-jp@jp.FreeBSD.org Fri Jan 19 10:16:05 2007
Received: (from daemon@localhost)
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) id l0J1G5f74659;
	Fri, 19 Jan 2007 10:16:05 +0900 (JST)
	(envelope-from owner-doc-jp@jp.FreeBSD.org)
Received: from andre (201-14-163-225.jvece7008.dsl.brasiltelecom.net.br [201.14.163.225] (may be forged))
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) with ESMTP/inet id l0J1Fnw74632;
	Fri, 19 Jan 2007 10:15:51 +0900 (JST)
	(envelope-from Australia'svariegating@acat.com)
Received: from 193.154.108.164 (HELO mailhost.acat.com)
     by jp.freebsd.org with esmtp (6H3EXI84.2** 60(9)
     id S6U1K0-..2V0(-?B
     for cvsupadm@jp.freebsd.org; Fri, 19 Jan 2007 01:16:29 +0180
From: "Tina Richardson" <Australia'svariegating@acat.com>
To: <cvsupadm@jp.FreeBSD.org>
Message-ID: <01c73b67$72c7b770$6c822ecf@Australia'svariegating>
MIME-Version: 1.0
Content-Type: text/plain;
	charset="iso-8859-1"
Content-Transfer-Encoding: 7bit
X-Priority: 3 (Normal)
X-MSMail-Priority: Normal
X-Mailer: Microsoft Office Outlook, Build 11.0.5510
X-MimeOLE: Produced By Microsoft MimeOLE V6.00.2800.1478
Thread-Index: Aca6Q0=?8((,K52-+35X(,52KMO17<==
X-Antivirus: avast! (VPS 0704-0, 18/01/2007), Outbound message
X-Antivirus-Status: Clean
Reply-To: doc-jp@jp.FreeBSD.org
Precedence: list
Date: Fri, 19 Jan 2007 01:16:29 +0180
X-Sequence: doc-jp 30548
Subject: [doc-jp 30548] {subj190107}
Sender: owner-doc-jp@jp.FreeBSD.org
X-Originator: Australia'svariegating@acat.com
X-Distribute: distribute version 2.1 (Alpha) patchlevel 24e+060209

No more scam or bad companies.
Look at charts and ask your broker about:

Ventana Medical Systems

Ventana Receives FDA Approval on Pathway

Thursday January 18, 10:08 am ET
Ventana Medical Systems Receives FDA Approval for Breast Cancer Detection Test

TUCSON, Ariz. (AP) -- Ventana Medical Systems Inc., a maker of tissue and slide preparation systems used in drug development, said Wednesday it received Food and Drug Administration approval on a new antibody.
The company received the approval for its Pathway Her-2/neu (4B5) Rabbit Monoclonal Antibody as an aid in assessing breast cancer patients being considered for treatment with Herceptin. It is also approved for use on the Ventana Image Analysis System.
Herceptin is a cancer treatment made by Genentech Inc. It targets HER-2, which causes breast cancer cells to grow more rapidly. The approved Pathway antibody is intended to detect the presence of the HER-2 antigen.

Get in before most investors hear about this awesome news!  VMSI has just made an announcement which, once the investment community hears about it, is going to send the issue rise!  Read on to find why we are so excited!


